Kura Oncology, Inc. (KURA) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Kura Oncology reported revenue of $67.5M, up 25.2% from $53.9M the year before. Net income was -$278.7M (a -412.9% net margin), or -$3.18 per diluted share. Operating margin was -449.9%. Operating activities generated -$64.1M of cash, leaving -$70.7M of free cash flow. At fiscal year end, Kura Oncology held $738.4M in total assets against $564.2M in total liabilities, including $149.1M of cash and equivalents.
Open the full interactive Kura Oncology financials → Quarterly statements, key ratios, valuation history and price charts.
Kura Oncology Key Stats
| Share Price | $9.83 |
|---|---|
| Market Cap | $873.4M |
| Revenue YoY Growth | +25.2% |
| 52-Week Range | $7.40 – $13.59 |
| Shares Outstanding | 88.9 million (basic, 2026 Q2) |
Kura Oncology Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $53.9M | $67.5M |
| Operating Income | — | — | — | — | -$193.2M | -$303.6M |
| Pre-Tax Income | -$89.6M | -$130.5M | -$135.8M | -$152.6M | -$172.0M | -$278.4M |
| Income Tax | $0 | $0 | $0 | $0 | $2.0M | $297,000 |
| Net Income | -$89.6M | -$130.5M | -$135.8M | -$152.6M | -$174.0M | -$278.7M |
| Diluted EPS | -$1.69 | -$1.97 | -$2.03 | -$2.08 | -$2.02 | -$3.18 |
Kura Oncology Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $20.8M | $17.3M | $18.3M | $20.9M |
| Net Income | -$74.1M | -$81.0M | -$73.3M | -$68.3M |
| Diluted EPS | -$0.85 | -$0.92 | -$0.83 | -$0.77 |
Kura Oncology Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $325.5M | $90.7M | $51.8M | $37.3M | $224.5M | $149.1M |
| Current Assets | $637.3M | $522.3M | $446.4M | $432.5M | $744.8M | $708.7M |
| Total Assets | $647.2M | $534.1M | $456.3M | $448.9M | $760.2M | $738.4M |
| Current Liabilities | $26.0M | $22.5M | $24.1M | $35.3M | $78.7M | $117.0M |
| Total Long-Term Debt | $7.2M | — | $9.2M | $9.3M | $9.5M | $9.7M |
| Total Liabilities | $36.3M | $27.4M | $36.0M | $51.7M | $346.5M | $564.2M |
| Shareholders' Equity | $610.9M | $506.6M | $420.3M | $397.3M | $413.6M | $174.1M |
Kura Oncology Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$69.8M | -$104.6M | -$110.1M | -$124.8M | $134.3M | -$64.1M |
| Cash From Investing | -$99.9M | -$126.8M | $32.6M | $15.6M | -$101.6M | -$13.1M |
| Cash From Financing | $469.3M | -$3.4M | $38.6M | $94.8M | $154.4M | $1.8M |
| Free Cash Flow | -$72.0M | -$105.7M | -$110.7M | -$125.0M | $133.8M | -$70.7M |
Figures from Kura Oncology's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Kura Oncology financials page for every line item.
Kura Oncology Company Profile
| Ticker | KURA |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | San Diego, California |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001422143 |
Frequently Asked Questions
What was Kura Oncology's revenue in fiscal 2025?
Kura Oncology (KURA) reported revenue of $67.5M for fiscal 2025.
What is Kura Oncology's annual revenue history?
Kura Oncology's annual revenue by fiscal year: 2020: $0; 2021: $0; 2022: $0; 2023: $0; 2024: $53.9M; 2025: $67.5M.
What was Kura Oncology's net income in fiscal 2025?
Kura Oncology reported net income of -$278.7M for fiscal 2025.
What was Kura Oncology's earnings per share (EPS) in fiscal 2025?
Kura Oncology's diluted EPS was -$3.18 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Kura Oncology generate in fiscal 2025?
Kura Oncology generated -$70.7M of free cash flow in fiscal 2025.
What was Kura Oncology's revenue last quarter?
In its most recent reported quarter (2026 Q2), Kura Oncology reported revenue of $20.9M.
How much debt does Kura Oncology have?
Kura Oncology reported $9.7M of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of Kura Oncology are outstanding?
Kura Oncology reported a weighted average of 88.9 million basic shares outstanding in 2026 Q2.
What is Kura Oncology's market cap?
Based on its latest closing price, Kura Oncology (KURA) has a market capitalization of about $873.4M.
When does Kura Oncology's fiscal year end?
Kura Oncology's fiscal year end, as registered with the SEC, is December 31.
Where is Kura Oncology headquartered?
Kura Oncology lists its business address in San Diego, California in its SEC filings.